Glioblastoma del adultoFase 1NCT04573140Artículos
ARNm tumoral total autólogo
Vacunas de partículas lipídicas de ARN (ARN-LP) para gliomas pediátricos de alto grado (GAGp) y glioblastoma (GBM) del adulto recién diagnosticados
Terapia génica de doble carga mediada por AAV en pacientes con glioma de alto grado
Lo que dice el vídeo
Glioblastoma is the most common cancer that starts in the adult brain. About eleven thousand people in the United States hear that diagnosis each year, most of them in their sixties. The standard plan is surgery, then radiation with a chemotherapy pill. It helps, but rarely finishes the job. In the trial that set today's standard, half of patients lived under fifteen months.
The reason is the shape of the thing. A glioblastoma has no edge. Its cells wander off into healthy brain, so surgery cannot reach them all. And a few of those cells behave like stem cells. Given time, they rebuild the whole tumor.
So imagine a gene that could kill those cells. Could you put it into a brain safely?
That is the real problem. Delivery is not the hard part; address is. Anything strong enough to kill a tumor cell will damage a neuron if it switches on in the wrong place. Gene therapies handle this with a promoter, a piece of DNA that works as an on switch for a nearby gene. But the switches available are either too weak or too leaky.
So a team in Edinburgh built a better switch.
Start with enhancers. An enhancer is a short piece of DNA that proteins land on to turn a gene up. In nature they cluster into super-enhancers, and those clusters are what give a cell its identity. The team asked whether they could build one from scratch, tuned to glioblastoma.
They began with the two proteins that keep a glioblastoma stem cell in its stem state, SOX two and SOX nine. They chopped the places those proteins bind into short fragments, tested about four and a half thousand of them one at a time, kept the ones that fired only in tumor cells, and chained the winners together. The result is a synthetic super-enhancer. In tumor stem cells it is as strong as the strongest switch in common use. In normal cells it is almost silent.
Then they wired two payloads behind it.
The first is an enzyme borrowed from the cold-sore virus. On its own it does nothing. But it converts a harmless antiviral pill into a drug that poisons dividing cells, so the tumor makes the poison that kills it.
The second is interleukin twelve, an alarm that calls in the immune system. Sent through the bloodstream it is far too toxic. Made inside tumor cells, it stays where it is needed. And because both payloads ride one message, the alarm fades as the tumor cells die.
In mice with an aggressive glioblastoma, one injection cleared the tumor in twenty of twenty-four animals, and they stayed well eleven months. Given fresh tumor cells months later, ten of them grew no tumor at all. Only about a fifth of the tumor cells had to receive the gene. The immune system found the rest.
Mice are not people, and earlier attempts at this kind of therapy struggled in the clinic. That is what this trial is for. It is called ADePT. About sixty-eight adults with new or returning glioblastoma get one injection into the tumor, then the antiviral pill for up to three weeks, then their planned surgery. The first questions are safety and dose. It runs at the Royal Infirmary of Edinburgh with Faye Robertson, and at Ohio State with Bradley Elder.
Everything in this film comes from the published record, and it is not medical advice.
Fuentes de este vídeo
Most common cancer that starts in the adult brain; ~11,000 US cases a year; most in their sixties
Most common cancer that starts in the adult brain; ~11,000 US cases a year; most in their sixties; Payload one: enzyme from the cold-sore virus turns a harmless antiviral pill into a poison for dividing cells; Both payloads on one message, so the alarm fades as tumor cells die; ADePT; ~68 adults; new or returning glioblastoma; one injection, antiviral pill up to three weeks, then planned surgery; safety and dose first (+1 more lines)
Stupp R. N Engl J Med, 2005
Surgery, then radiation with a chemotherapy pill; half of patients lived under fifteen months
Koeber U. Nature, 2026
No edge; cells wander into healthy brain; a few behave like stem cells and rebuild the tumor; Existing on switches are too weak or too leaky; Enhancers; clusters called super-enhancers define cell identity; Built around SOX2 and SOX9 (+10 more lines)
ADePT; ~68 adults; new or returning glioblastoma; one injection, antiviral pill up to three weeks, then planned surgery; safety and dose first
El fármaco
TGX-007 administrado en una única inyección intratumoral
Valaciclovir oral administrado 3 veces al día durante 14-21 días
Los pacientes recibirán TGX-007 mediante inyección intratumoral directa y después tomarán el profármaco valaciclovir por vía oral durante un máximo de 21 días antes de la cirugía estándar. El estudio se divide en dos fases. La fase I tratará a pacientes con distintos niveles de dosis de TGX-007 para identificar la dosis biológica óptima, que se usará para ampliar el estudio a la fase II.
El estudio
El objetivo de este ensayo clínico es definir primero la seguridad y la dosis biológica óptima (DBO) del fármaco en estudio TGX-007, y después investigar más a fondo su seguridad y eficacia en pacientes con glioblastoma recién diagnosticado o recurrente. TGX-007 es un fármaco de terapia génica administrado mediante un vector de virus adenoasociado (AAV) inocuo, que transporta dos cargas terapéuticas combinadas para permitir la destrucción de las células en proliferación y la activación de una respuesta inmunitaria antitumoral.
Una es la timidina quinasa del virus del herpes simple (HSV-tk), que convierte el profármaco valaciclovir en un fármaco activo capaz de destruir células tumorales, y la otra es la interleucina 12 (IL-12), que activa al sistema inmunitario para reconocer y combatir el tumor. Pueden ser elegibles los pacientes con glioblastoma recién diagnosticado aptos para cirugía y quimiorradioterapia estándar, o los pacientes con glioblastoma recurrente aptos para una nueva cirugía.
Requisitos
Criterios de inclusión tal como figuran en el registro, recortados. La lista completa, con las exclusiones, está en el registro actualizado.
Para ti, o para alguien a quien quieres
Un diagnóstico complejo trae preguntas nuevas cada semana, dentro de un ensayo y fuera de él. Triangle reúne todo tu expediente médico, lo lee contigo en lenguaje claro y te ayuda, a ti y a tu familia, a decidir qué preguntar después.
Después, $9 al mes. Cancela cuando quieras.
Solicitados a tus hospitales y clínicas a través de las redes nacionales. Añade estudios de imagen, patología y cualquier documento en papel.
Informes explicados a medida que llegan, con valores de laboratorio que puedes seguir antes del tratamiento, durante un ensayo y después.
Pregunta sobre tu propio expediente y llega con preguntas para tu oncólogo o el equipo del ensayo.
Comparte un mismo perfil con la familia que te ayuda y con tus médicos.
Los miembros también reciben un análisis profundo de sus historiales y de cualquier dato de secuenciación, incluidos los ensayos clínicos que podrían encajar, revisado por un médico colegiado antes de recibirlo.
Se convierte en un proyecto que hay que manejar: citas, estudios de imagen, análisis, efectos secundarios y papeleo. Triangle lo mantiene organizado en un solo lugar, para ti o para quien te ayuda.
Organizar mi ensayoPrueba gratuita de 7 días, después $9 al mes. Cancela cuando quieras.
Cómo funcionan estos ensayos: qué es de verdad la fase 1 · preguntas frecuentes No es evidencia clínica.